Oncogene TUBA1C promotes migration and proliferation in hepatocellular carcinoma and predicts a poor prognosis

Wang, Ji; Chen, Wei; Wei, Weiwei; Lou, Jianying

doi:10.18632/oncotarget.21894

Cited by 39 publications

(45 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, previous studies demonstrated TUBA1C upregulation could significantly impact tumor growth and progression (28,29). In addition, it was reported that TUBA1C has emerged as a critical intermediary in the cell cycle signaling pathway (21). Furthermore, recently studies found that knockdown of β-tubulin enhances the ability of vinca alkaloids to arrest mitosis and consequently induce apoptosis (30).…”

Section: Discussionmentioning

confidence: 99%

“…plays pivotal roles in various cancers (19). Moreover, TUBA1C, a subtype of α-tubulin, which is composed of microtubule structure, was reported to be overexpressed and predicts poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma (HCC) (20,21). However, the relevant effect of TUBA1C in PDAC patients has not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle

Albahde

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease and has the worst prognosis and survival rate. TUBA1C is a microtubule component implicated in multiple cancers, however, the clinical significance and biological functions of TUBA1C in the progression of PDAC remain unexplored. Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) data were employed to detect the TUBA1C mRNA expression and the relation between TUBA1C expression and overall survival (OS) in PDAC. Then, bioinformatic analysis was employed to determine the potential pathway and genes related to TUBA1C. Human pancreatic cancer tissue and adjacent non-tumor tissues samples were detected by immunochemistry (IHC) staining, and the correlation between TUBA1C expression and the clinicopathological features were investigated. Meanwhile, TUBA1C expression in PDAC cell lines was evaluated by western blotting. Furthermore, functional assays including cell viability, apoptosis, cell cycle, transwell assay, wound healing assay, and a xenograft tumor model were performed to determine the oncogenic role of TUBA1C in PDAC, respectively. Results: TUBA1C was overexpressed in the PDAC tissues and cells. IHC analysis showed that the TUBA1C overexpression was associated with short OS. Bioinformatic analysis indicated that TUBA1C overexpression was mainly associated with cell cycle regulation. The downregulation of TUBA1C significantly suppressed cell proliferation, induced cell apoptosis and cycle arrest, and inhibited invasion and migration in PDAC cells. Furthermore, TUBA1C downregulation also inhibited tumor growth in vivo. Albahde et al. Elevated TUBA1C Expression in PDAC Conclusion: These findings suggested that TUBA1C downregulation suppressed PDAC aggressiveness via cell cycle pathway and that TUBA1C may serve as a potential prognostic marker for PDAC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle

Albahde

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…As for TUBA1C, a component of tubulin is highly expressed in tumor tissues than the normal tissues according to previous studies (25). Ji Wang et al reported that TUBA1C may promote the migration and proliferation of hepatoma cells possibly through the cell cycle signal pathway (26). As for FBXO17, previous results showed that FBXO17 expression in tumor tissues of hepatocellular carcinoma (HCC) patients was markedly higher than that in adjacent tissues (27).…”

Section: Discussionmentioning

confidence: 94%

STXBP5L and its related molecules as potential biomarkers in lymph node metastatic breast cancer

Gao¹,

Shen

Shi

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLymph node metastasis is a common problem in breast cancer, and its underlying molecular mechanism is still unclear. The purpose of this study is to research the molecular mechanism and to explore the key RNAs and pathways that mediate lymph node metastasis in breast cancer.MethodsGSE100453 and GSE38167 were downloaded from the Gene Expression Omnibus (GEO) database and 569 breast cancer statistics were also downloaded from the TCGA database. Differentially expressed miRNAs were calculated by using R software and GEO2R. Gene ontology and Enriched pathway analysis of target mRNAs were analyzed by using DAVID and R software. The PPI network was constructed by using Metascape and Cytoscape software.ResultsIn total, 6 differentially expressed miRNAs were selected, and 499 mRNAs were identified after filtering. The research of KEGG indicated that mRNAs enriched in many cancer pathways. Besides, some hub mRNAs were analyzed after constructing the PPI network. A total of 3 out of 6 miRNAs had a significant relationship with the overall survival (P<0.05) and showed a good ability of risk prediction model of over survival.ConclusionBy utilizing bioinformatics analyses, differently expressed miRNAs were identified and constructed a complete gene network. Several potential mechanisms and therapeutic and prognostic targets of lymph node metastasis were also demonstrated in breast cancer.

show abstract

“…TUBA1C involves in hepatocellular carcinoma cell migration and proliferation, probability through cell cycle pathway. And TUBA1C is a potential prognostic biomarker of hepatocellular carcinoma [26]. PMM2 expression is significantly correlated with poor prognosis in renal cell carcinoma [27].…”

Section: Discussionmentioning

confidence: 99%

Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer

Xiao

2020

Bioengineered

View full text Add to dashboard Cite

Advanced colorectal cancer (CRC) is a significant cause of cancer mortality, with a poor prognosis. Here, we identified a novel prognostic signature for predicting survival of advanced CRC. Advanced CRC data were used (training set: n = 267 and validation set: n = 264). The survival analyses were investigated. The functional analysis of the prognostic signature was examined. In this study, our 15-gene signature was established and was an independent prognostic factor of advanced CRC. Stratification analyses also showed that this signature was still powerful for survival prediction in each stratum of age, gender, stage, and metastasis status. In mechanism, our signature involved in DNA replication, DNA damage, and cell cycle. Therefore, our findings suggested that this 15-gene signature has prognostic and predictive value in advanced CRC, which could be further used in personalized therapy for advanced CRC. ARTICLE HISTORY

show abstract

Oncogene TUBA1C promotes migration and proliferation in hepatocellular carcinoma and predicts a poor prognosis

Cited by 39 publications

References 14 publications

Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle

Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle

STXBP5L and its related molecules as potential biomarkers in lymph node metastatic breast cancer

Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer

Contact Info

Product

Resources

About